Emyria : Hidden Gems Webinar Presentation

Emyria (ASX:EMD)

Hidden Gems Webinar | Michael Winlo, CEO

only	Emyria develops biopharmaceuticals
	guided by proprietary Real-World
usenal	Data collected with patients across a
wholly-owned clinical service
	subsidiary

1

Emyria provides care, generates data & develops treatments

only

Care

Data

5 clinical sites (Emerald Clinics) treating

One of the largest patient registries of

more than 40 complex conditions in

ethically sourced Real-WorldData (RWD)

>6,000 patients aged 2-98.

on treatment effects of GMP-grade

usenal

cannabinoids to guide biopharmaceutical

development.

Patients

New

'Trial-grade'

Dose

with unmet

Real-World

response

treatments

needs

Data (RWD)

insights (IP)

Treatments

2 FDA-compliant drug development

programs seeking registration with major global regulators. More in development.

		Proprietary		Global
			registration
		drug design
			programs

2

See ASX Announcement 19 October 2021

[1]https://www.coherentmarketinsights.com/market-insight/post-traumatic-stress-disorder-treatment-market-4433

Registration of first FDA-compliantCBD for multiple indications

Screen and expand library of novel MDMA analogues

Emyria's active clinical development programs

			Platform
only
	Ultra-pure
	cannabinoid-based
	medical treatments
	(CBMTs)
usenal

Next-generation

MDMA analogues

Active program

EMD-RX5

MDMA

analogues

Initial opportunity

Over-the-counter treatment for psychological distress $200m/yr (Australia alone)

See ASX Announcement 19 October 2021

Eg. Advanced treatment +

therapies for PTSD

US$990m / yr (Global) [1]

Next 3-6 months

• Complete pivotal trials
• TGA registration application
• New formulations
• Launch US registration programs

• Advanced compound screening
• Commence animal studies
• Expand library
• Additional IP filings

Biopharmaceutical cannabinoid development

nal use only

4

Extensive Real-World Data (RWD) on cannabinoid treatments:

6,000 patients and counting

only	0-1,200mg
What dose?
				Range of daily CBD prescribed
			44
What problem?
				Unique primary indications
use
2 - 98 years
Which patients?
				age range of patients

0-197mg

Range of daily THC prescribed

53%

Patients presenting with symptoms

of depression

56%

female patients

7.12

Average concomitant medications

per patient at initial visit

54%

Patients presenting with symptoms of

moderate to severe anxiety

35%

Patients experiencing an adverse

event

nal

Data summary as of 28 FEB 2022		5